Open AccessRetrospective study of efficacy of adjuvant chemotherapy using tegafur-uracil in patients with non-small cell lung cancer with primary tumor size of 4.1–5.0 cm
Author(s) -
Hiroyuki Adachi,
Teppei Nishii,
Taketsugu Yamamoto,
Takuya Nagashima,
Yoshihiro Ishikawa,
Koji Ando,
Tekkan Woo,
Takamitsu Maehara,
Haruhiko Nakayama,
Munetaka Masuda
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.07.05
Subject(s) - medicine , hazard ratio , tegafur , stage (stratigraphy) , lung cancer , retrospective cohort study , confidence interval , adjuvant , guideline , adjuvant therapy , oncology , adjuvant chemotherapy , gastroenterology , surgery , cancer , pathology , breast cancer , paleontology , biology
The staging of patients with a tumor of diameter 4.1-5.0 cm and no lymphatic/distant metastases have been up-graded to stage IIA in the latest 8th edition of the TNM staging system. However, the efficacy of adjuvant tegafur-uracil (UFT) therapy in these patients, which has been recommended in the guideline issued by The Japan Lung Cancer Society, remains unclear. We evaluated the efficacy of adjuvant UFT therapy among a cohort by retrospective analyses of multicentric database.